Price
No data yet.
Social Signal Score
Revenue
$8.75M+236.52%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Brent Ashton
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 105
- Beta
- 0.03
- Country
- CA
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 8.03
Financials
Revenue
$8.75M+236.5%Net Income
$1.10MEBITDA
$1.17MFree Cash Flow
$-1.33M-687.5%EPS (diluted)
$0.04Shares Outstanding (diluted)
27.72M+92.2%Operating Expenses
$4.29MCash & Debt
$16.61MReturn of Capital
$0.00Dividend per Share
$0.11Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.82M | $2.06M | $0.08 |
| 2024 | $31.17M | $2.67M | $0.11 |
| 2023 | $26.60M | $-4.46M | $-0.18 |
| 2022 | $18.15M | $-9.66M | $-0.38 |
| 2021 | $19.56M | $23.48M | $0.08 |
| 2020 | $25.80M | $-7.81M | $-0.30 |
| 2019 | $34.00M | $-10.03M | $-0.45 |
| 2018 | $26.72M | $1.62M | $0.07 |
| 2017 | $27.31M | $1.81M | $0.09 |
| 2016 | $6.71M | $-3.10M | $-0.26 |
| 2015 | $7.59M | $-942.0K | $-0.10 |
| 2014 | $9.06M | $2.40M | $0.26 |
| 2013 | $4.13M | $-993.2K | $-0.11 |
| 2012 | $3.79M | $-3.99M | $-0.48 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.11
- Implied price
- $3.09
- Return from $1.66
- 13.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.54 — -7.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 20 | 24 | 28 | 32 | 36 |
|---|---|---|---|---|---|
| -2.0% | -3.9% | -0.4% | 2.7% | 5.5% | 8.0% |
| 3.0% | 1.0% | 4.7% | 8.0% | 10.9% | 13.5% |
| 8.0% | 5.9% | 9.8% | 13.2% | 16.3% | 19.1% |
| 13.0% | 10.8% | 14.9% | 18.5% | 21.7% | 24.6% |
| 18.0% | 15.7% | 20.0% | 23.7% | 27.1% | 30.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80Social Signal Score
Mentions (1)
- Newsbusinesswire.com·6h ago·Negative
Covalon Reports Fiscal 2026 Third Quarter Results MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 third quarter results for the period ended June 30, 2026. Full financial statements and management's discussion and analysis are available on the Company's profile at www.sedarplus.ca. Brent Ashton, Covalon's Chief Executive Officer, commented, “Covalon's…
View source ↗
Earnings
Thu, Dec 10(in 3 months)
Consensus estimate $0.02 per share
Typical surprise +121.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 27$0.07 vs $0.01beat
- Thu, May 21$0.03 vs $0.01beat
- Wed, Feb 25$0.00 vs $0.03miss
- Thu, Dec 11$0.01 vs $-0.03beat
- Thu, Aug 21$0.00 vs $-0.04beat
- Wed, May 28$0.01 vs $0.01beat
Estimates and results for CVALF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.